The Latest on Pliant Therapeutics' INTEGRIS-PSC Trial and Market Response
Thursday, 6 June 2024, 17:33
Pliant Therapeutics Shares Steady Amidst a Positive Outlook
Market analysts reaffirm their buy rating for Pliant Therapeutics, emphasizing the company's resilience in the face of market fluctuations.
Investor Interest in Phase 2 INTEGRIS-PSC Trial
In a positive development, Pliant Therapeutics' shares maintain a price target following the Phase 2 INTEGRIS-PSC trial, signaling investor confidence in the company's strategic direction.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.